title: The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
abstract: OBJECTIVE
  Data on the role of angiogenesis inhibitors (AIs) in the treatment of elderly patients with advanced non-small-cell lung cancer (NSCLC) remains limited. We aimed to assess the overall efficacy of AIs-containing regimens in the treatment of advanced NSCLC in this setting.
  
  
  METHODS
  Databases from PubMed, Web of Science, and abstracts presented at American Society of Clinical Oncology (ASCO) meeting up to October 31, 2014 were searched to identify relevant studies. Eligible studies included prospective randomized controlled trials (RCTs) evaluating therapies with or without AIs in elderly patients with advanced NSCLC. The endpoints were overall survival (OS) and progression-free survival (PFS). Statistical analyses were conducted by using random effects models and 95% confidence intervals (CIs) were calculated.
  
  
  RESULTS
  A total of 3,709 elderly patients with advanced NSCLC from 11 RCTs were identified for analysis. The pooled results demonstrated that there was a clinical benefit in PFS for AIs-containing regimens (hazard ratio (HR) 0.88, 95%CI: 0.78-1.00, P = 0.053) when compared to non-AIs-containing regimens, but not for OS (HR 0.99, 95%CI: 0.90-1.10, P = 0.89). On subgroup analysis, similar results were found based on treatment line. No publication bias was detected by Begg's and Egger's tests for OS.
  
  
  CONCLUSIONS
  In elderly patients with advanced NSCLC, AIs-containing therapies offer a clinical benefit in PFS but for OS. With present available data from RCTs, we are still unable to clearly set the role of specific AIs in the treatment of advanced NSCLC in this setting.
authors.affiliation: Department of Respiratory, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Rong-Hua
authors.initials: RH
authors.lastname: Tian
authors.affiliation: Department of Respiratory, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Xia
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Respiratory, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Respiratory, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Jin-Wang
authors.initials: JW
authors.lastname: Yang
authors.affiliation: Department of Medical Affairs, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Hua-Liang
authors.initials: HL
authors.lastname: Ji
authors.affiliation: Department of Medical Affairs, Affiliated Haian People's Hospital of Nantong University, Haian, Jiangsu, Province of China.
authors.forename: Yong-Jin
authors.initials: YJ
authors.lastname: Yan
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D020533:Angiogenesis Inhibitors